bluebird bio Announces Receipt of Expected Notice from Nasdaq
26 Aprile 2024 - 10:05PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it
received a notice (the “notice”) on April 24, 2024 from The Nasdaq
Stock Market LLC (“Nasdaq”) stating that because the Company has
not yet filed its Annual Report on Form 10-K for the year ended
December 31, 2023 (the “2023 Form 10-K"), it is no longer in
compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which
requires listed companies to timely file all required periodic
financial reports with the Securities and Exchange Commission (the
“SEC”).
The notice has no immediate effect on the listing or trading of
the Company’s common stock on the Nasdaq. Under Nasdaq rules, the
Company has 60 calendar days from receipt of the notice, or until
June 24, 2024, to submit a plan to regain compliance with the
Rule.
On April 16, 2024, bluebird previously announced that it would
be delayed in filing its 2023 Form 10-K due to the need to restate
the Company’s consolidated financial statements as of and for the
year ended December 31, 2022 and unaudited financial information
for each of the first three quarters of 2023 and 2022 in its 2023
Form 10-K. The notice from Nasdaq is standard practice in the event
of a delayed 10-K filing and was anticipated.
The Company is continuing to work expeditiously to complete the
filing of the 2023 Form 10-K as promptly as possible. As previously
reported, the restatements relate to the identification of embedded
leases and the treatment of non-lease components contained in lease
agreements. The Company does not expect the restatements to result
in any impact on its cash position or revenue.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements that are not statements of historical facts
are, or may be deemed to be, forward-looking statements, such as
statements regarding the Company’s restatement of certain
historical financial statements and impact on cash position and
revenue, the filing of its 2023 Form 10-K and submission of a plan
to regain compliance with the Rule. Such forward-looking statements
are based on historical performance and current expectations and
projections about bluebird’s future goals, plans and objectives and
involve inherent risks, assumptions and uncertainties, including
internal or external factors that could delay, divert or change any
of them in the next several years, that are difficult to predict,
may be beyond bluebird’s control and could cause bluebird’s future
goals, plans and objectives to differ materially from those
expressed in, or implied by, the statements. No forward-looking
statement can be guaranteed. Forward-looking statements in this
press release should be evaluated together with the many risks and
uncertainties that affect bluebird bio’s business, particularly
those identified in the risk factors discussion in bluebird bio’s
Annual Report on Form 10-K for the year ended December 31, 2022, as
updated by its subsequent Quarterly Reports on Form 10-Q, Current
Reports on Form 8-K and other filings with the SEC. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, bluebird bio undertakes no obligation to publicly
update or revise any forward-looking statement, whether as a result
of new information, future events, changed circumstances or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426834938/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni bluebird bio (NASDAQ:BLUE)
Storico
Da Mag 2023 a Mag 2024